Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Opioid drugs bind to opioid receptors that are present in several areas of the nervous system such as the brain and spinal cord. Medically, they are primarily being used for pain relief. The drug class primarily used in relieving pain includes natural, semi-synthetic, and synthetic opioids. However, its application is not limited to pain relief alone and has been successfully used for treatment of various other medical conditions such as diarrhea and cough. Opioid drugs can be broadly divided into two categories, mild and major opioids, on the basis of its efficacy. Opioids can be administered as oral pills, parenteral, liquids, patches, or lozenges. Overdose and drug abuse is a major concern, with the situation alarming in developed regions. According to World Drug Report 2017, 29.5 million people suffered from drug use disorders in 2015 and staggering 70% of this 29.5 million were attributed to opioids only.
Market Dynamics
Incidence of chronic pain, which is primarily treated by opioids has witnessed continuous growth over the last decades. According to a report titled Pain in Europe, published in 2006, chronic pain affected around one in five (19%) adults, and prevalence was recorded to be the highest in Norway, Poland, and Italy, where one-fourth of adults were suffering from chronic pain. According to a study titled Prevalence of Chronic Pain in the UK, published in The BMJ (British Medical Journal), in 2013, chronic pain affects between one-third and one-half of the population in the U.K, indicating high prevalence rate. Prevalence rate is similar in other developed countries such as the U.S. Rapidly increasing incidence of chronic pain is thus expected to boost growth of the opioids market over the forecast period.
However, increasing usage of opioids, has led to increase in its overuse or abuse over the recent past. To tackle this situation, CDC published guidelines for prescribing opioids for chronic pain. Similar efforts to curtail opioid overuse are underway in developed economies of Europe. Such intervention by regulatory bodies are expected to obstruct growth of the opioids market.
Key Features of the Study:
This report provides in-depth analysis of the opioids market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 – 2024, considering 2014 & 2015 as the base years
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global opioids market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Purdue Pharma L.P., Titan Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Janssen Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Egalet Corporation, Endo Pharmaceuticals Inc., Allergan, Plc, and Pfizer Inc.
Insights from this report will allow marketers and the management authorities of companies to make informed decision with respect to their future product launch, technology upgrades, market expansion, and marketing tactics
The global opioids market report caters to various stakeholders in this industry, including investors, geriatric care service providers, assistive device manufacturers, distributors and suppliers, research and consulting firms, new entrants, and financial analysts
Various strategy matrices used in analyzing the opioids market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:
Global Opioids Market, By Drug Class:
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
Global Opioids Market, By Therapeutic Application:
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Global Opioids Market, By Geography:
North America
U.S.
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Canada
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Europe
U.K.
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Germany
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Italy
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
France
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Spain
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Russia
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Rest of Europe
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Asia-Pacific
China
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
India
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Japan
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
ASEAN
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Australia
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
South Korea
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Rest of Asia Pacific
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Latin America
Brazil
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Mexico
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Argentina
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Rest of Latin America
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Middle East
GCC
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Israel
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Rest of Middle East
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Africa
North Africa
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Central Africa
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
South Africa
By Drug Class
Agonist
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Diphenoxylate
Hydromorphone
Methylphenidate
Oxycodone
Oxymorphone
Antagonist
Buprenorphine
Naloxone
Naltrexone
Methylnaltrexone
Nalbuphine
By Therapeutic Application
Pain Management
Neuropathic Pain
Migraine
Back Pain
Osteoarthritis Pain
Cancer Pain
Others
Cough Treatment
Diarrhea Treatment
Company Profiles
Purdue Pharma*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Titan pharmaceuticals
Boehringer Ingelheim
Janssen Pharmaceuticals, Inc.
Sanofi
Sun Pharmaceuticals
Mallinckrodt Pharmaceuticals
Egalet Corporation
Endo Pharmaceuticals Inc.
Allergan, Plc
Pfizer Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
? Market Definition and Scope
o Executive Summary
? Market Snippet, By Drug Class
? Market Snippet, By Therapeutic Application
? Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
? Drivers
? Restraints
? Market Opportunities
o Regulatory Scenario
o Reimbursement Scenario
o Pricing Analysis
o New Product Launches
o Government Policies and Initiatives
4. Global Opioids Market, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
o Introduction
? Market Share Analysis, 2015 and 2024 (%)
? Y-o-Y Growth Analysis, 2014 - 2024
? Segment Trends
o Agonist
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
• Codeine
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
• Fentanyl
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
• Meperidine
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
• Methadone
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
• Morphine
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
• Hydrocodone
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
• Diphenoxylate
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
• Hydromorphone
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
• Methylphenidate
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
• Oxycodone
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
• Oxymorphone
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
o Antagonist
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
• Buprenorphine
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
• Naloxone
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
• Naltrexone
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
• Methylnaltrexone
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
• Nalbuphine
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
5. Global Opioids Market, By Therapeutic Application, 2014 - 2024 (US$ Million & No. of Units)
o Introduction
? Market Share Analysis, 2015 and 2024 (%)
? Y-o-Y Growth Analysis, 2014 - 2024
? Segment Trends
o Pain Management
? Introduction
? Market Share Analysis, 2015 and 2024 (%)
? Y-o-Y Growth Analysis, 2014 - 2024
• Neuropathic Pain
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
• Migraine
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
• Back Pain
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
• Osteoarthritis Pain
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
• Cancer Pain
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
• Others
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
o Cough Treatment
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
o Diarrhea Treatment
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
6. Global Opioids Market, By Regions, 2014 - 2024 (US$ Million & No. of Units)
o Introduction
? Market Share Analysis, By Region, 2015 and 2024 (%)
? Y-o-Y Growth Analysis, For Regions, 2014 - 2024
o North America
? Market Share Analysis, By Country, 2015 and 2024 (%)
? Y-o-Y Growth Analysis, By Country, 2014 - 2024
• U.S.
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• Canada
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
o Europe
? Market Share Analysis, By Country, 2015 and 2024 (%)
? Y-o-Y Growth Analysis, By Country, 2014 - 2024
• U.K.
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• Germany
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• Italy
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• France
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• Russia
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• Rest of Europe
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
o Asia Pacific
? Market Share Analysis, By Country, 2015 and 2024 (%)
? Y-o-Y Growth Analysis, By Country, 2014 - 2024
• China
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• India
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• Japan
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• ASEAN
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• Australia
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• South Korea
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• Rest of Asia Pacific
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
o Latin America
? Market Share Analysis, By Country, 2015 and 2024 (%)
? Y-o-Y Growth Analysis, By Country, 2014 - 2024
• Brazil
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• Mexico
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• Rest of Latin America
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
o Africa
? Market Share Analysis, By Country, 2015 and 2024 (%)
? Y-o-Y Growth Analysis, By Country, 2014 - 2024
• Northern Africa
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• Central Africa
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• South Africa
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
o Middle East
? Market Share Analysis, By Country, 2015 and 2024 (%)
? Y-o-Y Growth Analysis, By Country, 2014 - 2024
• GCC Countries
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• Israel
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
• Rest of Middle East
? Country Trends
? Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
? Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis (3x3 Matrix)
o Company Profiles
? Purdue Pharma
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Plans
? Titan Pharmaceuticals
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Plans
? Boehringer Ingelheim
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Plans
? Janssen Pharmaceuticals, Inc.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Plans
? Sanofi
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Plans
? Mallinckrodt Pharmaceuticals
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Plans
? Egalet Corporation
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Plans
? Endo Pharmaceuticals Inc
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Plans
? Allergan Plc
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Plans
? Pfizer Inc.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Plans
? Sun Pharmaceuticals
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Plans
o Analyst Views
8. Section
o References
o Research Methodology
o About Us and Sales Contact
*Browse 130 market data tables and 42 figures on "Opioids Market - Global forecast to 2024".
